Oncolys BioPharma Inc. (4588.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−67.9x

Market Cap

JPY 104.70B

MomentumView details →

1D Return

−0.49%

YTD Return

+232.01%

RSI (14)

67.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−67.9x

Market Cap

JPY 104.70B

RSI (14)

67.2

MomentumView details →

1D Return

−0.49%

YTD Return

+232.01%

ProfitabilityView details →

Gross Margin

101.95%

Net Margin

−7350.00%

EBITDA Margin

−7227.71%

ROE (TTM)

−51.46%

ROA (TTM)

−45.18%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−9.68%

EPS YoY

−1.53%

FCF YoY

—

Revenue CAGR 3Y

−69.39%

EPS CAGR 3Y

−3.67%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

9.55x

Quick Ratio

9.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

31.55M

Net Income (TTM)

−1.66B

Op. CF (TTM)

—

Next earningsNov 6, 2026 →

Latest newsMore news →

On September 1, 2026, four stocks hit limit-up and four hit limit-down at the close on the Tokyo Stock Exchange, including Brain's Technology, DeltaFly Pharma, Asterisk, and others.4d ago

Oncolys BioPharma announced that results of a Phase 2a clinical trial of LINE-1 inhibitor senzavudine for progressive supranuclear palsy were published in the overseas medical journal 'Movement Disorders'.8d ago

Similar companies

Nxera Pharma Co.,Ltd.4565.T Mochida Pharmaceutical Co.,Ltd.4534.T ZERIA PHARMACEUTICAL CO.,LTD.4559.T PeptiDream Inc.4587.T EIKEN CHEMICAL CO.,LTD.4549.T GNI Group Ltd.2160.T Find similar companies →

Latest newsMore news →

On September 1, 2026, four stocks hit limit-up and four hit limit-down at the close on the Tokyo Stock Exchange, including Brain's Technology, DeltaFly Pharma, Asterisk, and others.4d ago Oncolys BioPharma announced that results of a Phase 2a clinical trial of LINE-1 inhibitor senzavudine for progressive supranuclear palsy were published in the overseas medical journal 'Movement Disorders'.8d ago